Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
Agomab Appoints Industry Veteran David Epstein as Chairman of its Board of Directors
Agomab Receives FDA Orphan Drug Designation for AGMB-447 in Idiopathic Pulmonary Fibrosis
Agomab Starts Phase 1 Clinical Study for AGMB-447 in Pulmonary Fibrosis
Agomab Appoints Angelika Jahreis as Member of the Board of Directors
Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline
A week after entering its lead asset into a phase 2 trial for a type of Crohn’s disease, Agomab Therapeutics has secured $100 million in series C financing to power up its pipeline.
Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
GHENT, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab’) today announced it has extended its Series B financing round with an additional close of $40.5 million (€38.4 million), bringing the total Series B amount raised to $114 million. Pfizer led the extension with an investment through its Pfizer Breakthrough Growth Initiative, which provides funding and access to Pfizer’s scientific expertise to support biotechnology companies’ most promising clinical development programs. Walleye Capital and Asabys Partners also participated in the extension as new Agomab investors, along with existing investors. The initial Series B close of $74 million, led by Redmile Group, was announced in March 2021.